China Medical Technologies (中国医疗技术公司) was granted SFDA approval for a bladder cancer FISH probe, an advanced molecular diagnostic test kit that uses DNA probes for early detection and monitoring of bladder cancer. The probe detects whether human bladder cells show aneuploidy (an unusual number of chromosomes) for chromosomes 3, 7, 17 and loss of the p16 locus. Several China hospitals use the probes for diagnosing patients with hematuria (red blood cells in the urine) and have diagnosed patients with early-stage bladder cancer as well as early-stage ureteral cancer, which caused hematuria in these patients. More details...

Stock Symbol: (NSDQ: CMED)